Overview
Steris fiscal Q2 revenue grows 10%
Adjusted EPS for fiscal Q2 exceeds analyst estimates
Company raises fiscal 2026 outlook for organic revenue and adjusted EPS
Outlook
Company raises fiscal 2026 constant currency organic revenue growth to 7-8%
STERIS expects fiscal 2026 adjusted EPS to be $10.15-$10.30
Company anticipates fiscal 2026 free cash flow of approximately $850 mln
Result Drivers
HEALTHCARE SEGMENT - Healthcare revenue grew 9% driven by service and consumable sales, offset by tariff costs and inflation
APPLIED STERILIZATION TECHNOLOGIES - AST revenue rose 10% with growth in service revenue despite a decline in capital equipment sales
LIFE SCIENCES SEGMENT - Life Sciences revenue increased 13%, led by 39% growth in capital equipment sales
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Adjusted EPS | Beat | $2.47 | $2.35 (8 Analysts) |
Q2 Adjusted Net Income | Beat | $244.50 mln | $230.96 mln (5 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for STERIS plc is $280.00, about 13.6% above its November 4 closing price of $241.85
Press Release: ID:nGNX1YFQr5
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)